A Phase 3 interventional study of Levodopa-carbidopa intestinal gel and CADD-Legacy® 1400 ambulatory infusion pump in Dyskinesias, Parkinson's Disease and Severe Motor Fluctuations, sponsored by AbbVie (prior sponsor, Abbott). Completed at 22 sites in 3 countries. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2015-01-16.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies in Dyskinesias with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyskinesias · United States.
Among the 101 studies in Dyskinesias with a site in United States, this one is the 36th largest by enrollment of the 82 interventional ones that give a count, is one of 7 that started in 2009, is one of 24 in phase 3, and was the 23rd registered.
179 studies on the registry are indexed under Dyskinesias; 24 are open to participants now.
Browse Dyskinesias studies →8 of the 101 studies in Dyskinesias with a site in United States are open now. Recruiting first, the newest first:
Appello Pharmaceuticals, Inc. · Sites in United States
Ages 30–80
U: The Mind Company · Sites in United States
Ages 18–80
Boston Children's Hospital · Sites in United States
Ages 0–30
Boston Children's Hospital · Sites in United States
Ages 0–18
Boston Children's Hospital · Sites in United States
Ages 0–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Dyskinesias studies recruiting now, 4 (25%) set no upper age limit and 8 (50%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 38 · Phase 3 28 · Phase 4 3
First in 1999; this study’s year is marked. 7 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is above the median of 36 across 139 interventional studies indexed under Dyskinesias.
Median enrollment 41 across the 82 interventional studies, 36 across the 18 observational. Of the 85 that completed or were terminated, 33 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 101 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
AbbVie has 7 studies filed under Dyskinesias — fewer than ten, so there is no comparison to draw.
2 of the studies in Dyskinesias with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06618157Duke UniversityConnectomic Guided DBS for Parkinson's Disease | 2026-12-29 |
| NCT07432958Appello Pharmaceuticals, Inc.A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations | 2027-09-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 101 studies in Dyskinesias with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.
Study S187.3.003 (NCT00360568) is a Phase 3, 12-month, open-label, multicenter continuation treatment study of the safety, tolerability, and efficacy of levodopa-carbidopa intestinal gel (LCIG) in the treatment of participants with levodopa-responsive Parkinson's disease (PD) with persistent motor fluctuations despite optimized treatment with available PD medications. All participants received LCIG.
Only participants who completed 12 weeks of double-blind, double-dummy treatment in Study S187.3.001 or S187.3.002 (NCT00357994/ NCT00660387) qualified for enrollment in this 12-month continuation treatment study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks). Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances.
Drug: Levodopa-carbidopa intestinal gel · Device: CADD-Legacy® 1400 ambulatory infusion pump · Device: PEG tube · Device: J-tube
Drug pages: Levodopa · Carbidopa
Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
percutaneous endoscopic gastrostomy tube
jejunal tube
Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs
AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.
Time frame: From study enrollment to the end of study or early termination of treatment, including the removal of PEG-J, plus 30 days.
Number of Participants With Device Complications
Complications of the infusion device were collected. Pump, intestinal tube, PEG, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and device site reaction.
Time frame: 12 months
Number of Participants With Potentially Clinically Significant Values for Hematology Parameters
Terms abbreviated in the table include females (f) and males (m).
Time frame: 12 months
Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters
Terms abbreviated in the table include upper limit of normal (ULN), male (m), and female (f).
Time frame: 12 months
Number of Participants With Potentially Clinically Significant Vital Sign Parameters
Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.
Time frame: 12 months
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters
Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.
Time frame: 12 months
Number of Participants With Sleep Attacks at Baseline and Endpoint
To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and Post-baseline (PBL)
The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire-setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.
Time frame: Baseline, Post-baseline (up to Month 12)
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint
The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions concerning problems with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia \[involuntary muscle movement\]).
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Number of Participants With Confirmed Cases of Melanoma
A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination/end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.
Time frame: up to Month 12
Number of Participants With Clinically Significant Neurological Examination Findings
The neurologic examination was to be done during "On" time. The neurological examination assessed: cranial nerves - assessment of cranial nerves II - XII, excluding fundoscopic examination; motor system - assessment of tone, strength, and abnormal movements; sensory system - including light touch, pinprick, joint position, and vibratory sense; reflexes - assessment of deep tendon reflexes and plantar responses (Babinski sign); coordination - assessment of upper and lower extremities; gait - assessment of base and tandem gait; station - assessment of posture and stability.
Time frame: up to 12 months
Columbia-Suicide Severity Rating Scale (C-SSRS) Findings
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.
Time frame: up to 12 months
Number of Participants Taking at Least 1 Concomitant Medication During the Study
Concomitant medications include medications started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.
Time frame: 12 months
Change From Baseline in Average Daily "Off" Time at Endpoint
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Month 12
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. "On" time without troublesome dyskinesia (involuntary muscle movement) is defined as "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for "on" time without troublesome dyskinesia indicates improvement.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint
The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Endpoint
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 representing no disability.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint
The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint
The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'
Time frame: Baseline, Endpoint (Month 12 or last post-baseline visit)
Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint
The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=quite frequently, and 4=nearly always). The caregiver burden is evaluated by the total score (range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.
Time frame: Baseline, Endpoint (Month 12 months or last post-baseline visit)
| Milestone | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) |
|---|---|---|
| Started | 33 | 29 |
| Completed | 31 | 24 |
| Not completed | 2 | 5 |
| Withdrew: Adverse event | 1 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 |
AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Deaths | 0 | 0 | 0 |
| TE Deaths | 0 | 0 | 0 |
| >=1 SAE | 5 | 9 | 14 |
| >=1 TESAE | 5 | 9 | 14 |
| >=1 TEAE Leading to Study Termination | 1 | 2 | 3 |
| >=1 TEAE | 31 | 28 | 59 |
| >=1 Severe TEAE | 5 | 10 | 15 |
| >=1 Possibly or ProbablyTreatment-Related TEAE | 28 | 20 | 48 |
| No TEAEs | 2 | 1 | 3 |
Complications of the infusion device were collected. Pump, intestinal tube, PEG, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and device site reaction.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| >=1 Complication | 26 | 24 | 50 |
| Pump Complication | 18 | 16 | 34 |
| Intestinal Tube Complication | 15 | 16 | 31 |
| PEG Complication | 11 | 11 | 22 |
| Stoma Complication | 12 | 15 | 27 |
| Other | 6 | 4 | 10 |
Terms abbreviated in the table include females (f) and males (m).
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Red Blood Cells <2.0 10^12/L (f); <2.5 10^12/L (m) | 0 | 0 | 0 |
| Haemoglobin <90 g/L (f); <100 g/L (m) | 0 | 1 | 1 |
| Haematocrit <30% (f); <34% (m) | 1 | 1 | 2 |
| White Blood Cells <2.8 10^9/L | 0 | 0 | 0 |
| White Blood Cells >16.0 10^9/L | 0 | 0 | 0 |
| Neutrophils, Absolute <1.2 10^9/L | 0 | 0 | 0 |
| Lymphocytes >80% | 0 | 0 | 0 |
| Lymphocytes, Absolute <.75 10^9/L | 2 | 0 | 2 |
| Eosinophils >10% | 0 | 0 | 0 |
| Monocytes >30% | 0 | 0 | 0 |
| Platelet Count <95 10^9/L | 0 | 0 | 0 |
| Platelet Count >700 10^9/L | 0 | 0 | 0 |
| Mean Corpuscular Volume <60 fL | 0 | 0 | 0 |
| Mean Corpuscular Volume >120 fL | 0 | 0 | 0 |
Terms abbreviated in the table include upper limit of normal (ULN), male (m), and female (f).
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Sodium <126 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Sodium >156 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Albumin <25 g/L; n=27, 20, 47 | 0 | 0 | 0 |
| Albumin >70 g/L; n=27, 20, 47 | 0 | 0 | 0 |
| Potassium <3.0 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Potassium >6.0 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Creatinine >177 µmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Calcium <1.75 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Calcium >3.0 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Total Protein <45 g/L; n=33, 28, 61 | 0 | 0 | 0 |
| Total Bilirubin >2xULN; n=33, 28, 61 | 0 | 0 | 0 |
| Aspartate Aminotransferase >3xULN; n=33, 28, 61 | 0 | 0 | 0 |
| Alanine Aminotransferase >3xULN; n=33, 28, 61 | 0 | 0 | 0 |
| Gamma-glutamyl Transpeptidase >3x ULN;n=33, 28, 61 | 1 | 1 | 2 |
| Lactate dehydrogenase >3x ULN; n=33, 28, 61 | 0 | 0 | 0 |
| Alkaline Phosphatase >400 U/L; n=33, 28, 61 | 0 | 0 | 0 |
| Creatine Phosphokinase >3x ULN; n=33, 28, 61 | 0 | 0 | 0 |
| Non-fasting Glucose <2.78 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Non-fasting Glucose >16.0 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Uric Acid>500µmol/L(f);>590µmol/L(m);n=33, 28, 61 | 0 | 0 | 0 |
| Blood Urea Nitrogen >10.8 mmol/L; n=28, 22, 50 | 3 | 0 | 3 |
| Cholesterol >12.9 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
| Triglycerides >5.6 mmol/L; n=33, 28, 61 | 0 | 0 | 0 |
Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| SuSBP <=90 and >30 mm Hg ↓ from BL; n=33, 29, 62 | 3 | 0 | 3 |
| SuSBP >=180 and >40 mm Hg ↑ from BL; n=33, 29, 62 | 1 | 2 | 3 |
| StSBP <=90 and >30 mm Hg ↓ from BL; n=33, 29, 62 | 4 | 7 | 11 |
| StSBP >=180 and >40 mm Hg ↑ from BL; n=33, 29, 62 | 0 | 0 | 0 |
| OSBP: ↓ >=30 mm Hg Supine to Standing; n=33,29,62 | 8 | 11 | 19 |
| SuDBP <=50 and >30 mm Hg ↓ from BL; n=33, 29, 62 | 0 | 1 | 1 |
| SuDBP >=105 and >30 mm Hg ↑ from BL; n=33, 29, 62 | 1 | 1 | 2 |
| StDBP <=50 and >30 mm Hg ↓ from BL; n=33, 29, 62 | 1 | 0 | 1 |
| StDBP >=105 and >30 mm Hg ↑ from BL; (n=33,29,62) | 2 | 1 | 3 |
| ODBP: ↓ >=20 mm Hg Supine to Standing; n=33,29,62 | 7 | 7 | 14 |
| SuP <=50 and >30 bpm ↓ from BL; n=33, 29, 62 | 1 | 0 | 1 |
| SuP >=120 and >30 bpm ↑ from BL; n=33, 29, 62 | 0 | 0 | 0 |
| StP <=50 and >30 bpm ↓ from BL; n=33, 29, 62 | 0 | 0 | 0 |
| StP >=120 and >30 bpm ↑ from BL; n=33, 29, 62 | 0 | 1 | 1 |
| Temp >=38.3° and >=1.1°C ↑ from BL; n=33, 29, 62 | 0 | 0 | 0 |
| Weight <=7% ↓ from BL; n=33, 27, 60 | 5 | 5 | 10 |
| Weight >=7% ↑ from BL; n=33, 27, 60 | 8 | 8 | 16 |
Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| HR <=50 and >30 bpm ↓ from BL; n=33, 28, 61 | 0 | 0 | 0 |
| HR >=120 and >30 bpm ↑ from BL; n=33, 28, 61 | 0 | 0 | 0 |
| PR Interval <120 msec; n=33, 27, 60 | 1 | 0 | 1 |
| PR Interval >220 msec; n=33, 27, 60 | 1 | 0 | 1 |
| QTcB Interval >480 msec; n=33, 27, 60 | 0 | 0 | 0 |
| QTcB Interval >60 msec ↑ from BL; n=33, 27, 60 | 0 | 0 | 0 |
| QTcF Interval >480 msec; n=33, 27, 60 | 0 | 0 | 0 |
| QTcF Interval >60 msec ↑ from BL; n=33, 27, 60 | 0 | 0 | 0 |
To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Participants with >=1 Sleep Attacks at Baseline | 0 | 0 | 0 |
| Participants with >=1 Sleep Attacks at Endpoint | 0 | 0 | 0 |
The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire-setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| BL Pathological Gambling; n=33, 29, 62 | 0 | 0 | 0 |
| BL Trichotillomania; n=33, 29, 62 | 0 | 0 | 0 |
| BL Kleptomania; n=33, 29, 62 | 0 | 0 | 0 |
| BL Pyromania; n=33, 29, 62 | 0 | 0 | 0 |
| BL Intermittent Explosive Disorder; n=33, 29, 62 | 0 | 0 | 0 |
| BL Compulsive Buying; n=33, 29, 62 | 0 | 1 | 1 |
| BL Compulsive Sexual Behavior; n=33, 29, 62 | 0 | 1 | 1 |
| PBL Pathological Gambling; n=33, 27, 60 | 0 | 0 | 0 |
| PBL Trichotillomania; n=33, 27, 60 | 0 | 0 | 0 |
| PBL Kleptomania; n=33, 27, 60 | 0 | 0 | 0 |
| PBL Pyromania; n=33, 27, 60 | 0 | 0 | 0 |
| PBL Intermittent Explosive Disorder; n=33, 27, 60 | 0 | 0 | 0 |
| PBL Compulsive Buying; n=33, 27, 60 | 1 | 0 | 1 |
| PBL Compulsive Sexual Behavior; n=33, 27, 60 | 2 | 0 | 2 |
The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions concerning problems with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia \[involuntary muscle movement\]).
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline; n=33, 29, 62 | 6.1 ± 6.0 | 5.3 ± 6.3 | 5.7 ± 6.1 |
| Change from Baseline at Endpoint; n=33, 27, 60 | 6.1 ± 6.0 | 5.0 ± 6.3 | 5.6 ± 6.1 |
A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination/end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Number of Participants With Confirmed Cases of Melanoma | 0 | 0 | 0 |
The neurologic examination was to be done during "On" time. The neurological examination assessed: cranial nerves - assessment of cranial nerves II - XII, excluding fundoscopic examination; motor system - assessment of tone, strength, and abnormal movements; sensory system - including light touch, pinprick, joint position, and vibratory sense; reflexes - assessment of deep tendon reflexes and plantar responses (Babinski sign); coordination - assessment of upper and lower extremities; gait - assessment of base and tandem gait; station - assessment of posture and stability.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Cranial Nerve | 0 | 0 | 0 |
| Motor System | 3 | 2 | 5 |
| Sensory System | 2 | 1 | 3 |
| Reflexes | 1 | 1 | 2 |
| Coordination | 1 | 0 | 1 |
| Gait | 2 | 2 | 4 |
| Station | 2 | 2 | 4 |
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Participants with Suicidal Ideations | 0 | 0 | 0 |
| Participants with Suicidal Ideations Only | 0 | 0 | 0 |
| Participants with Suicidal Behaviors | 0 | 0 | 0 |
| Participants with Suicidal Behaviors or Ideations | 0 | 0 | 0 |
Concomitant medications include medications started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.
| participants | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Number of Participants Taking at Least 1 Concomitant Medication During the Study | 33 | 29 | 62 |
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.
| hours | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 2.87 ± 2.18 | 5.18 ± 2.05 | 3.92 ± 2.40 |
| Change from Baseline at Endpoint | -0.42 ± 2.67 | -2.34 ± 2.78 | -1.30 ± 2.86 |
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.
| hours | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 1.09 ± 2.07 | 0.82 ± 1.54 | 0.97 ± 1.84 |
| Change from Baseline at Endpoint | -0.58 ± 2.18 | 0.15 ± 2.17 | -0.24 ± 2.19 |
Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. "On" time without troublesome dyskinesia (involuntary muscle movement) is defined as "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for "on" time without troublesome dyskinesia indicates improvement.
| hours | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 12.04 ± 2.42 | 10.00 ± 2.62 | 11.11 ± 2.69 |
| Change from Baseline at Endpoint | 1.00 ± 2.58 | 2.19 ± 3.70 | 1.54 ± 3.17 |
The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| CGI-S at Baseline; n=32, 28, 60 | 3.0 ± 1.3 | 3.7 ± 1.3 | 3.3 ± 1.3 |
| CGI-I at Endpoint; n=33, 29, 62 | 2.1 ± 1.2 | 2.3 ± 1.6 | 2.2 ± 1.4 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 1.6 ± 1.8 | 1.2 ± 1.0 | 1.4 ± 1.5 |
| Change from Baseline at Endpoint | 0.3 ± 1.9 | 0.7 ± 1.7 | 0.5 ± 1.8 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 8.6 ± 6.5 | 12.1 ± 7.0 | 10.1 ± 6.9 |
| Change from Baseline at Endpoint | 0.5 ± 3.4 | -1.0 ± 7.0 | -0.2 ± 5.3 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 16.2 ± 12.7 | 19.0 ± 10.5 | 17.4 ± 11.8 |
| Change from Baseline at Endpoint | 1.5 ± 7.0 | -0.5 ± 10.4 | 0.6 ± 8.6 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 representing no disability.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 26.4 ± 18.9 | 32.4 ± 16.1 | 29.0 ± 17.8 |
| Change from Baseline at Endpoint | 2.3 ± 9.0 | -1.0 ± 15.0 | 0.9 ± 12.0 |
The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 5.8 ± 2.7 | 7.0 ± 3.2 | 6.3 ± 3.0 |
| Change from Baseline at Endpoint | -1.6 ± 2.5 | -1.4 ± 3.0 | -1.5 ± 2.7 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 22.2 ± 17.3 | 32.8 ± 17.0 | 26.9 ± 17.8 |
| Change from Baseline at Endpoint | 1.5 ± 12.7 | -3.5 ± 13.4 | -0.7 ± 13.2 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 27.6 ± 24.1 | 43.8 ± 25.4 | 34.7 ± 25.8 |
| Change from Baseline at Endpoint | 2.3 ± 19.5 | -8.5 ± 18.6 | -2.5 ± 19.7 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 25.9 ± 24.8 | 39.4 ± 21.3 | 31.9 ± 24.1 |
| Change from Baseline at Endpoint | 0.4 ± 14.0 | -6.7 ± 19.9 | -2.8 ± 17.1 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 20.1 ± 20.3 | 26.3 ± 17.2 | 22.8 ± 19.1 |
| Change from Baseline at Endpoint | 4.0 ± 16.4 | 1.9 ± 18.1 | 3.1 ± 17.1 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 16.4 ± 21.3 | 23.8 ± 19.0 | 19.7 ± 20.5 |
| Change from Baseline at Endpoint | 0.2 ± 15.2 | -6.3 ± 20.7 | -2.7 ± 18.0 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 11.9 ± 18.2 | 17.1 ± 17.8 | 14.2 ± 18.0 |
| Change from Baseline at Endpoint | 1.8 ± 17.2 | -2.7 ± 15.5 | -0.2 ± 16.5 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 15.0 ± 14.1 | 24.8 ± 18.9 | 19.3 ± 16.9 |
| Change from Baseline at Endpoint | 1.3 ± 16.3 | 3.8 ± 16.7 | 2.4 ± 16.4 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 15.9 ± 16.3 | 31.7 ± 23.2 | 22.9 ± 21.0 |
| Change from Baseline at Endpoint | 8.3 ± 18.4 | -1.9 ± 15.3 | 3.8 ± 17.7 |
The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Endpoint | 32.1 ± 25.8 | 34.9 ± 22.9 | 33.3 ± 24.4 |
| Change from Baseline at Endpoint | -2.8 ± 18.8 | 1.0 ± 19.5 | -1.1 ± 19.0 |
The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 0.778 ± 0.144 | 0.676 ± 0.158 | 0.733 ± 0.158 |
| Change from Baseline at Endpoint | -0.009 ± 0.173 | -0.006 ± 0.220 | -0.008 ± 0.193 |
The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 76.7 ± 16.2 | 62.1 ± 22.0 | 70.2 ± 20.2 |
| Change from Baseline at Endpoint | -0.9 ± 15.1 | 4.5 ± 15.5 | 1.5 ± 15.4 |
The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=quite frequently, and 4=nearly always). The caregiver burden is evaluated by the total score (range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.
| units on a scale | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| Baseline | 22.1 ± 15.3 | 27.0 ± 17.2 | 24.3 ± 16.2 |
| Change from Baseline at Endpoint | 1.1 ± 9.7 | -1.8 ± 9.0 | -0.2 ± 9.4 |
Collected over From study enrollment to the end of study or early termination of treatment, including the removal of PEG-J (up to 52 weeks), plus 30 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LCIG (Previous: LCIG + Placebo Capsules) | — | 5/33 (15.2%) | 29/33 (87.9%) |
| LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | — | 9/29 (31%) | 26/29 (89.7%) |
| LCIG (All Participants) | — | 14/62 (22.6%) | 55/62 (88.7%) |
| Event | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| COMPLICATION OF DEVICE INSERTIONGeneral disorders | 1/33 | 2/29 | 3/62 |
| PNEUMONIAInfections and infestations | 0/33 | 2/29 | 2/62 |
| ANGINA PECTORISCardiac disorders | 0/33 | 1/29 | 1/62 |
| ABDOMINAL PAINGastrointestinal disorders | 1/33 | 1/29 | 2/62 |
| FAECALOMAGastrointestinal disorders | 0/33 | 1/29 | 1/62 |
| INTESTINAL ISCHAEMIAGastrointestinal disorders | 0/33 | 1/29 | 1/62 |
| INTESTINAL PERFORATIONGastrointestinal disorders | 0/33 | 1/29 | 1/62 |
| PERITONITISGastrointestinal disorders | 0/33 | 1/29 | 1/62 |
| ASTHENIAGeneral disorders | 1/33 | 1/29 | 2/62 |
| CHOLECYSTITISHepatobiliary disorders | 0/33 | 1/29 | 1/62 |
| Event | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | LCIG (All Participants) |
|---|---|---|---|
| INCISION SITE ERYTHEMAInjury, poisoning and procedural complications | 7/33 | 11/29 | 18/62 |
| VITAMIN B6 DECREASEDInvestigations | 8/33 | 5/29 | 13/62 |
| INSOMNIAPsychiatric disorders | 2/33 | 7/29 | 9/62 |
| FALLInjury, poisoning and procedural complications | 7/33 | 6/29 | 13/62 |
| POSTOPERATIVE WOUND INFECTIONInfections and infestations | 5/33 | 6/29 | 11/62 |
| CONSTIPATIONGastrointestinal disorders | 4/33 | 5/29 | 9/62 |
| NAUSEAGastrointestinal disorders | 4/33 | 5/29 | 9/62 |
| POST PROCEDURAL DISCHARGEInjury, poisoning and procedural complications | 3/33 | 5/29 | 8/62 |
| URINARY TRACT INFECTIONInfections and infestations | 5/33 | 4/29 | 9/62 |
| BLOOD HOMOCYSTEINE INCREASEDInvestigations | 5/33 | 2/29 | 7/62 |
| Age, Continuous(years) | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | Total |
|---|---|---|---|
| Mean | 63.6 ± 9.0 | 64.8 ± 6.6 | 64.1 ± 7.9 |
| Age, Customized(participants) | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | Total |
|---|---|---|---|
| <65 years | 19 | 13 | 32 |
| >=65 years | 14 | 16 | 30 |
| Sex: Female, Male(Participants) | LCIG (Previous: LCIG + Placebo Capsules) | LCIG (Previous: Placebo Gel + Levodopa-Carbidopa Capsules) | Total |
|---|---|---|---|
| Female | 10 | 8 | 18 |
| Male | 23 | 21 | 44 |
The record gives a start of Jun 2009, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2015, 2 years 3 months after primary completion. A results delay was requested in Oct 2013.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levodopa · Carbidopa
AbbVie (prior sponsor, Abbott) →